Enterprise Value

132.7M

Cash

94.52M

Avg Qtr Burn

-163K

Short % of Float

6.52%

Insider Ownership

2.26%

Institutional Own.

22.22%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Iomab-B (CD45) (apamistamab-I-131) Details
Hematopoietic cell transplantation , Acute myeloid leukemia

BLA

Submission

Iomab-ACT (GeneTx – CD45) Details
Lymphoma, Acute radiation syndrome

Phase 1/2

Data readout

Iomab-ACT (CAR-T – CD45) Details
Lymphoma, Diffuse large B cell lymphoma

Phase 1/2

Data readout

Actimab-A + venetoclax Details
Relapsed/refractory acute myeloid leukemia

Phase 1/2

Data readout

Actimab-A + CLAG-M Details
Relapsed/refractory acute myeloid leukemia

Phase 1

Data readout

Actimab-A + venetoclax Details
Myelodysplastic syndrome

Phase 1

Update